Risk Factors of Response to Neoadjuvant Chemotherapy in Patients with Luminal (HER2 Negative) Breast Cancer: Roc Curve and Logistic Regression Model Results

Basit Öğe Kaydı
dc.authorid0000-0002-1224-0090en_US
dc.authorid0000-0001-9333-6926en_US
dc.authorid0000-0003-2869-6620en_US
dc.authorid0000-0002-9430-8975en_US
dc.contributor.authorBozdogan, Atilla
dc.contributor.authorEmiroglu, Selman
dc.contributor.authorAbuaisha, Asmaa
dc.contributor.authorBaşar, Özlem Deniz
dc.date.accessioned2024-02-19T08:24:01Z
dc.date.available2024-02-19T08:24:01Z
dc.date.issued2024en_US
dc.departmentEnstitüler, Fen Bilimleri Enstitüsü, İstatistik Ana Bilim Dalıen_US
dc.description.abstractBackground: Neoadjuvant chemotherapy (NAC) is less effective for luminal human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC) patients and generally shows a low pathological complete response (pCR) after NAC compared to HER2 positive and triple negative breast cancer (TNBC). This study aimed to determine the factors associated with histopathologic response following NAC in luminal (HER2 negative) BC. Methods: This is a cross-sectional study conducted on 255 estrogen (ER) positive and HER2 negative BC patients after NAC between January 2018 and July 2023. Demographic and clinicopathological characteristics of the patients were collected for the statistical analysis. Chi-Square tests were used in the qualitative comparisons between study groups. Receiver Operating Characteristic (ROC) analysis was used for the diagnostic performance of Ki-67 expression and ER in determining the pCR rates. Using the Youden index, optimum cut points were determined. Also, multivariate logistic regression analysis was applied to determine the independent variables associated with the dependent variable (pCR). Results: After NAC, pCR was achieved in the breast in 35 (14%) patients, in the axilla in 44 (17%) patients, and in both the breast and axilla in 18 (7%) patients. Ki-67 expression was the only common variable associated with the breast, axilla and both the breast and axilla pCR. The most appropriate Ki-67 expression cut-off value for determining the breast and axilla complete response was found to be 40%. ER positivity level was only associated with pCR in the breast and the cut-off value was found to be 85%. Conclusion: The results of this study raise the possibility of patients with luminal (HER2 negative) BC with Ki-67 expression higher than 40% benefiting from chemotherapy, as they showed increased pCR rates.en_US
dc.identifier.doi10.32768/abc.202411167-74en_US
dc.identifier.endpage74en_US
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85184593530en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage67en_US
dc.identifier.urihttps://hdl.handle.net/11467/7141
dc.identifier.urihttps://doi.org/10.32768/abc.202411167-74
dc.identifier.volume11en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherFarname Scientific Publishing Inc.en_US
dc.relation.ispartofArchives of Breast Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - İdari Personel ve Öğrencien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLuminal breast cancer, Neoadjuvant therapy, HER2 negative, pathologic complete response, Ki-67en_US
dc.titleRisk Factors of Response to Neoadjuvant Chemotherapy in Patients with Luminal (HER2 Negative) Breast Cancer: Roc Curve and Logistic Regression Model Resultsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Risk-Factors-of-Response-to-Neoadjuvant-Chemotherapy-in-Patients-with-Luminal-HER2-Negative-Breast-Cancer-Roc-Curve-and-Logistic-Regression-Model-ResultsArchives-of-Breast-Cancer.pdf
Boyut:
378.63 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.56 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu